These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26348208)

  • 21. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
    Buch P; Langguth P; Kataoka M; Yamashita S
    J Pharm Sci; 2009 Jun; 98(6):2001-9. PubMed ID: 18855916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation.
    Pestieau A; Krier F; Lebrun P; Brouwers A; Streel B; Evrard B
    Int J Pharm; 2015 May; 485(1-2):295-305. PubMed ID: 25796121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
    Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-micellizing solid dispersions enhance the properties and therapeutic potential of fenofibrate: Advantages, profiles and mechanisms.
    Shi NQ; Zhang Y; Li Y; Lai HW; Xiao X; Feng B; Qi XR
    Int J Pharm; 2017 Aug; 528(1-2):563-577. PubMed ID: 28602799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
    Zhang L; Chai G; Zeng X; He H; Xu H; Tang X
    Drug Dev Ind Pharm; 2010 Sep; 36(9):1054-63. PubMed ID: 20818965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of different in vitro dissolution tests based on level A in vitro-in vivo correlations for fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Lebrun S; Cahay B; Brouwers A; Streel B; Cardot JM; Evrard B
    Eur J Pharm Biopharm; 2017 Mar; 112():18-29. PubMed ID: 27865930
    [No Abstract]   [Full Text] [Related]  

  • 27. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide.
    Bouledjouidja A; Masmoudi Y; Van Speybroeck M; Schueller L; Badens E
    Int J Pharm; 2016 Feb; 499(1-2):1-9. PubMed ID: 26732521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
    Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.
    Xu Y; Wang Y; Li XM; Huang Q; Chen W; Liu R; Chen B; Wei P
    Drug Dev Ind Pharm; 2014 Jul; 40(7):972-9. PubMed ID: 23692349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of fenofibrate microemulsion for improved bioavailability.
    Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
    Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of orally active hypolipidemic agents.
    Bandgar BP; Sarangdhar RJ; Khan F; Mookkan J; Shetty P; Singh G
    J Med Chem; 2011 Aug; 54(16):5915-26. PubMed ID: 21770455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
    Hu J; Ng WK; Dong Y; Shen S; Tan RB
    Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
    Mohsin K; Long MA; Pouton CW
    J Pharm Sci; 2009 Oct; 98(10):3582-95. PubMed ID: 19130605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches.
    Zhang H; Meng Y; Wang X; Dai W; Wang X; Zhang Q
    Drug Deliv; 2014 Dec; 21(8):588-94. PubMed ID: 24320001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate.
    Kanaujia P; Ng WK; Tan RB
    J Microencapsul; 2014; 31(3):293-8. PubMed ID: 24156747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of highly water-soluble fibrate derivatives via BGLation.
    Nemoto H; Kamiya M; Nakamoto A; Matsushita T; Matsumura K; Hattori H; Kawamura T; Taoka C; Abe S; Ishizawa K; Miyamoto L; Tsuchiya K
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6425-8. PubMed ID: 22975299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin.
    Damgé C; Vranckx H; Balschmidt P; Couvreur P
    J Pharm Sci; 1997 Dec; 86(12):1403-9. PubMed ID: 9423155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation of a Novel Form of Gelatin With a Three-Dimensional Ordered Macroporous Structure to Regulate the Release of Poorly Water-Soluble Drugs.
    Xu J; Zhao Z; Hao Y; Zhao Y; Qiu Y; Jiang J; Yu T; Ji P; Liu Y; Wu C
    J Pharm Sci; 2016 Sep; 105(9):2940-2948. PubMed ID: 26906173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.